Infrequently dosed, longer-acting antiretroviral agents are making adherence to medication easier, leading to better outcomes for those living with HIV or at risk of infection.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stevens, G. L. et al. Early Intervention Psych. 10, 365–377 (2016).
Segal‑Maurer, S. et al. N. Engl. J. Med. 386, 1793–1803 (2022).
Delany-Moretlwe, S. et al. Lancet 399, 1779–1789 (2022).
US Food and Drug Administration. https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection (accessed June 2022).
Dvory-Sobol, H., Shaik, N., Callebaut, C. & Rhee, M. S. Curr. Opin. HIV AIDS 17, 15–21 (2022).
Link, J. O. et al. Nature 584, 614–618 (2020).
Shoupe, D. Contracept. Reprod. Med. 1, 4 (2016).
Hosek, S. et al. J. Intl AIDS Soc. 19, 21107 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has received honoraria for advisory roles to Gilead Sciences, ViiV Health Care, Johnson and Johnson and Merck Pty Ltd.
Rights and permissions
About this article
Cite this article
Bekker, LG. Long-acting agents for HIV treatment and prevention. Nat Med 28, 1542–1543 (2022). https://doi.org/10.1038/s41591-022-01917-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-01917-w
